文献速递神经免疫

多发性硬化疾病活动与进展的新兴脑脊液生物标志物

Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2024-03-11

该队列研究利用两个前瞻性多发性硬化队列,在131例测试队列中分析25种脑脊液标志物与影像学指标的关系,并在68例确认队列中评估基线脑脊液胶质纤维酸性蛋白(GFAP)与长期确认的残疾进展(CDP24)的关联。结果显示活化的胶质标志物(尤其GFAP)和神经丝重链与非复发进展型疾病结局相关,且基线脑脊液GFAP升高与长期疾病进展相关。

要点

  • 脑脊液GFAP与缓慢扩大病灶(SEL)数量及T1低信号相关,而与急性炎症指标无关。
  • 神经丝重链与SEL数量及SEL内T1低信号相关。
  • 基线脑脊液GFAP升高与长期CDP24相关(HR 2.1,95%CI 1.3-3.4,P=.002)。

核心结论

  • 活化的胶质标志物(尤其GFAP)和神经丝重链与非复发进展型疾病结局相关,独立于急性炎症活动。
  • 脑脊液GFAP升高与长期多发性硬化疾病进展相关。

研究设计与样本

  • 队列研究,评估两个前瞻性多发性硬化队列的数据。
  • 测试队列为多中心研究,纳入复发型或原发进展型多发性硬化并开始抗CD20治疗的患者,收集系列脑脊液、临床和影像学评估(招募时间2016-2018年;分析时间2020-2023年)。
  • 确认队列为单中心队列,评估基线和长期(>10年)临床随访时的脑脊液(分析时间2022-2023年)。
  • 测试队列n=131,包括100例复发型多发性硬化(平均[SD]年龄36.6[10.4]岁;68例[68%]女性,32例[32%]男性;EDSS评分0-5.5)和31例原发进展型多发性硬化(平均[SD]年龄44.9[7.4]岁;15例[48%]女性,16例[52%]男性;EDSS评分3.0-6.5)。
  • 确认队列n=68,包括41例复发型多发性硬化和27例原发进展型多发性硬化,均在诊断时入组(年龄40岁[范围20-61岁];47例[69%]女性,21例[31%]男性)。

主要发现

  • 在测试队列中,GFAP与SEL计数相关(r=0.33),与SEL来源的T2病灶体积比例较高相关(r=0.24),与SEL内T1加权信号较低相关(r=-0.33),但与急性炎症指标不相关。
  • 神经丝重链与SEL计数相关(r=0.25),与SEL内T1加权信号较低相关(r=-0.28)。
  • 免疫标志物与急性炎症指标相关,且与GFAP不同,受抗CD20治疗影响。
  • 在确认队列中,较高的基线脑脊液GFAP水平与长期CDP24相关(风险比2.1;95%CI 1.3-3.4;P=.002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Biomarkers distinguishing nonrelapsing progressive disease biology from relapsing biology in multiple sclerosis (MS) are lacking. Cerebrospinal fluid (CSF) is an accessible fluid that most closely reflects central nervous system biology. OBJECTIVE: To identify CSF biological measures associated with progressive MS pathobiology. DESIGN, SETTING, AND PARTICIPANTS: This cohort study assessed data from 2 prospective MS cohorts: a test cohort provided serial CSF, clinical, and imaging assessments in a multicenter study of patients with relapsing MS (RMS) or primary progressive MS (PPMS) who were initiating anti-CD20 treatment (recruitment: 2016-2018; analysis: 2020-2023). A single-site confirmation cohort was used to assess CSF at baseline and long-term (>10 year) clinical follow-up (analysis: 2022-2023). EXPOSURES: Test-cohort participants initiated standard-of-care ocrelizumab treatment. Confirmation-cohort participants were untreated or received standard-of-care disease-modifying MS therapies. MAIN OUTCOMES AND MEASURES: Twenty-five CSF markers, including neurofilament light chain, neurofilament heavy chain, and glial fibrillary acid protein (GFAP); 24-week confirmed disability progression (CDP24); and brain magnetic resonance imaging measures reflecting focal injury, tissue loss, and progressive biology (slowly expanding lesions [SELs]). RESULTS: The test cohort (n = 131) included 100 patients with RMS (mean [SD] age, 36.6 [10.4] years; 68 [68%] female and 32 [32%] male; Expanded Disability Status Scale [EDSS] score, 0-5.5), and 31 patients with PPMS (mean [SD] age, 44.9 [7.4] years; 15 [48%] female and 16 [52%] male; EDSS score, 3.0-6.5). The confirmation cohort (n = 68) included 41 patients with RMS and 27 with PPMS enrolled at diagnosis (age, 40 years [range, 20-61 years]; 47 [69%] female and 21 [31%] male). In the test cohort, GFAP was correlated with SEL count (r = 0.33), greater proportion of T2 lesion volume from SELs (r = 0.24), and lower T1-weighted intensity within SELs (r = -0.33) but not with acute inflammatory measures. Neurofilament heavy chain was correlated with SEL count (r = 0.25) and lower T1-weighted intensity within SELs (r = -0.28). Immune markers correlated with measures of acute inflammation and, unlike GFAP, were impacted by anti-CD20. In the confirmation cohort, higher baseline CSF GFAP levels were associated with long-term CDP24 (hazard ratio, 2.1; 95% CI, 1.3-3.4; P = .002). CONCLUSIONS AND RELEVANCE: In this study, activated glial markers (in particular GFAP) and neurofilament heavy chain were associated specifically with nonrelapsing progressive disease outcomes (independent of acute inflammatory activity). Elevated CSF GFAP was associated with long-term MS disease progression.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Cross AH, Gelfand JM, Thebault S, et al. Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis. JAMA Neurol. 2024. PMID: 38466277. doi:10.1001/jamaneurol.2024.0017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。